October 3, 2005 -- Celgene said the FDA delayed a decision on its cancer drug Revlimid, based on concerns the drug may cause birth defects, Human Genome Sciences received a two-stage contract with the US government for its anthrax vaccine, Novartis reported more positive Phase II data for its new MS drug, Australian firm pSivida signed a merger deal with privately held Control Delivery Systems, Endo Pharma said its extended release opoid passed the second of two Phase III tests, Forbes Medi-Tech received FDA permission to proceed with a Phase II trial of a new cholesterol drug, Iomai filed for a $86 million IPO, and Allergan struck a deal with GlaxoSmithKline to promote Botox in Japan and China. The Centient Biotech 200 closed 22 points higher at 3780, a rise of .59%. More details...
